Vanguard Group Inc Cure Vac N.V. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Cure Vac N.V. stock. As of the latest transaction made, Vanguard Group Inc holds 71,768 shares of CVAC stock, worth $205,974. This represents 0.0% of its overall portfolio holdings.

Number of Shares

71,768

Previous 136,819 47.55%

Holding current value

$205,974

Previous $465,000 54.84%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$2.74 - $3.79 $178,239 - $246,543	-65,051 Reduced 47.55%	71,768 $210,000
Q2 2024 Aug 13, 2024	BUY	$2.31 - $4.99 $26,548 - $57,350	11,493 Added 9.17%	136,819 $465,000
Q1 2024 May 10, 2024	BUY	$2.94 - $4.34 $52 - $78	18 Added 0.01%	125,326 $379,000
Q3 2023 Nov 14, 2023	BUY	$6.5 - $10.77 $26,247 - $43,489	4,038 Added 3.33%	125,308 $855,000
Q2 2023 Aug 14, 2023	BUY	$6.69 - $12.25 $208,701 - $382,151	31,196 Added 34.63%	121,270 $1.26 Million
Q1 2023 May 15, 2023	BUY	$6.38 - $12.5 $102,022 - $199,887	15,991 Added 21.59%	90,074 $627,000
Q4 2022 Feb 10, 2023	BUY	$5.75 - $8.5 $7,475 - $11,050	1,300 Added 1.79%	74,083 $446,000
Q3 2022 Nov 14, 2022	BUY	$7.48 - $15.24 $164 - $335	22 Added 0.03%	72,783 $574,000
Q2 2022 Aug 12, 2022	SELL	$13.18 - $19.41 $323,779 - $476,826	-24,566 Reduced 25.24%	72,761 $990,000
Q1 2022 May 13, 2022	SELL	$14.73 - $35.25 $96,672 - $231,345	-6,563 Reduced 6.32%	97,327 $1.91 Million
Q4 2021 Feb 14, 2022	BUY	$33.72 - $48.22 $359,961 - $514,748	10,675 Added 11.45%	103,890 $3.56 Million
Q3 2021 Nov 12, 2021	BUY	$49.26 - $74.5 $534,323 - $808,101	10,847 Added 13.17%	93,215 $5.09 Million
Q2 2021 Aug 13, 2021	BUY	$56.91 - $127.53 $4.69 Million - $10.5 Million	82,368 New	82,368 $6.05 Million

Others Institutions Holding CVAC

# of Institutions

Shares Held

12.3M

Call Options Held

164K

Put Options Held

117K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Cure Vac N.V. Transaction History